CINCINNATI--(BUSINESS WIRE)--Devicor® Medical Products, Inc. (Devicor), a portfolio company of GTCR, a leading private equity firm, and Faxitron® Bioptics, LLC are pleased to announce a new distribution agreement for Faxitron’s CoreVision® in the United States and abroad. CoreVision® verifies the presence of micro-calcifications in core biopsies, rapidly confirming a successful biopsy procedure directly in the stereotactic biopsy suite.
Faxitron’s CoreVision® is sold to breast radiologists, breast surgeons and clinicians around the world. The use of purpose-built, point-of-care specimen radiography like Faxitron’s CoreVision®, is to minimize patient discomfort through shorter procedure times that also allow for workflow efficiencies and more room turns.
“Our strategy is focused on providing best-in-class technology that increases the accuracy of breast cancer detection while facilitating more efficient clinical practice,” said Devicor CEO Tom Daulton. “Faxitron’s CoreVision® is perfectly aligned with our mission, and is highly complementary with our current products, including Mammotome revolve® and the Mammotome MammoTestTM stereotactic biopsy table.”
The agreement includes the newly co-branded Mammotome CoreVision® within the United States, with impending distribution in other countries in Europe and Asia.
“This joint venture is one of the most exciting events in our company’s history,” said Faxitron CEO Paul Murtagh. “Together, our combined market presence will help us reach more hospitals and breast centers and provide the equipment needed to redefine procedural efficiency.”
About Faxitron® Bioptics, LLC
Faxitron is the world’s largest and only fully vertically integrated, dedicated cabinet x-ray company. With an installed base of over 7,000 systems in medical facilities and scientific and industrial research laboratories around the globe, Faxitron is the pioneer and industry standard in cabinet x-ray systems for specimen radiography, research, and NDT applications. For more than 40 years, Faxitron has defined cabinet x-ray by developing x-ray sensor technology and innovative systems to meet the evolving needs of our customers.
About Devicor® Medical Products, Inc.
Devicor Medical Products, headquartered in Cincinnati, Ohio, has more than 400 employees around the world. As the global market leader, Devicor is committed to advancing technology to help clinicians accurately diagnose breast disease, such as breast cancer, through minimally invasive procedures. Devicor’s product portfolio includes the world-renowned Mammotome® Breast Biopsy System, Mammotome revolve®, the tetherless Mammotome elite®, Neoprobe® Gamma Detection System (GDS), Mammotome MammoTestTM stereotactic biopsy table, as well as a comprehensive portfolio of tissue markers used in breast disease diagnostic sampling and management. These products are sold in more than 50 countries around the world. Since its introduction in 1995, more than four million women have had a minimally invasive breast biopsy in stereotactic, ultrasound or MRI-guidance imaging using the Mammotome® Breast Biopsy System. For more information, please visit www.devicormedical.com or www.mammotome.com.
Founded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Financial Services & Technology, Healthcare and Information Services & Technology industries. The Chicago-based firm pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth. Since its inception, GTCR has invested more than $10 billion in over 200 companies. For more information, please visit www.gtcr.com.